title: Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems.
abstract: Quantitated automated electro-oculographic data from 45 parkinsonian patients were compared with those from 30 normal control subjects. Patients were selected with idiopathic Parkinson's disease without other associated neurological disease or dementia; 20 had never received antiparkinsonian drugs and in 25 such treatment had been stopped for at least 2 days. Saccade latency, amplitude and peak velocity, smooth pursuit peak velocity, optokinetic nystagmus (OKN) maximal and mean velocities and vestibulo-ocular reflex (VOR) suppression by vision or imagination were significantly altered in patients, whereas VOR gain in darkness was normal. Alterations of saccade latency and smooth pursuit peak velocity were more severe in the more advanced stages of the disease and saccade latency directed towards the symptomatic side was slightly delayed in hemiparkinsonian patients. Saccade amplitude improved 90 min after a single oral dose of L-DOPA. These results suggest a possible dopaminergic control of some ocular movements.
authors: Department of Medical and Clinical Pharmacology (INSERM U317), Centre Hospitalier Universitaire Purpan, Toulouse, France.
authors: O
authors: O
authors: Rascol
authors: M
authors: M
authors: Clanet
authors: J L
authors: JL
authors: Montastruc
authors: M
authors: M
authors: Simonetta
authors: M J
authors: MJ
authors: Soulier-Esteve
authors: B
authors: B
authors: Doyon
authors: A
authors: A
authors: Rascol
mesh_terms: D000328:Adult; D000368:Aged; D004298:Dopamine / Q000502:physiology*; D004585:Electrooculography; D005133:Eye Movements; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy / Q000503:physiopathology*; D012027:Reflex, Vestibulo-Ocular; D012720:Severity of Illness Index
chemical_list: D007980:Levodopa; D004298:Dopamine